Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by MONTANARI, C.
Right arrow Articles by SANESI, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MONTANARI, C.
Right arrow Articles by SANESI, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1976 Oxford University Press

research-article

CLINICAL TRIAL WITH AMANTADINE AND PEMOLINE IN ELDERLY PATIENTS

C. MONTANARI*, G. F. VALLECORSI, A. BAVAZZANO, G. D'AYALAVALVA and P. SANESI

Geriatric Department Ospedale Generale Provinciale della Misericordia e Dolce, Prato, Italy

In a controlled clinical trial, amantadine 400 mg daily, 200 mg daily and 200 mg daily given with 20 mg of pemoline daily were compared with placebo in the treatment of elderly patients suffering from involutional cerebropathy characterized by psychomotor slowing down. The results showed that amantadine 400 mg daily was superior to placebo but was associated with a high incidence of side-effects (37 per cent), amantadine 200 mg daily was not superior to placebo but when pemoline 20 mg daily was added the combination was superior to placebo and few side-effects were reported.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.